Core Insights - Scienture Holdings, Inc. has formalized multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli, which will provide access to over 2,500 healthcare institutions across the U.S. [1][5] - The company aims to penetrate approximately 20% of the U.S. institutional market with Arbli, a novel liquid formulation of losartan potassium, a widely prescribed hypertension medication [2][4]. - The U.S. losartan market is valued at around $256 million in annual sales, with a prescription volume of 71 million, and currently, all marketed products are in oral solid form [6]. Company Developments - Arbli is FDA-approved for treating hypertension in patients over six years old and for reducing stroke risk in patients with hypertension and left ventricular hypertrophy, as well as treating diabetic nephropathy in certain type 2 diabetes patients [4]. - Arbli is the first and only FDA-approved, ready-to-use oral liquid losartan available in the U.S., which does not require compounding, offering reduced dosing volume and a long-term shelf life at room temperature [5]. - The company recently announced a registered direct offering of 3.225 million shares at $1.20 per share, generating gross proceeds of approximately $3.9 million [6]. Market Position - The agreements with GPOs and Pharmacy Benefit Managers (PBMs) are significant for securing formulary access with health plans covering over 100 million lives [3]. - Scienture's stock was down 0.16% at $0.84 during premarket trading, near its 52-week low of $0.69 [7].
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions